Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone
- 31 March 1997
- Vol. 20 (3), 259-261
- https://doi.org/10.1016/s8756-3282(96)00368-7
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Skeletal safety of tiludronateBone, 1995
- Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized studyAmerican Journal Of Medicine, 1995
- Comparative prospective, double‐blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of paget's disease of boneArthritis & Rheumatism, 1995
- Long-term effects of intravenous pamidronate in fibrous dysplasia of boneThe Lancet, 1994
- Mineralisation defects with pamidronate therapy for Paget's diseaseThe Lancet, 1993
- Dynamic Radiologic Patterns of Paget??s Disease of BoneClinical Orthopaedics and Related Research, 1987
- Long-Term Follow-up Observations on Treatment in Paget??s Disease of BonePublished by Wolters Kluwer Health ,1987
- ETIDRONATE AND THE RISK OF FRACTURESThe Lancet, 1985
- Effects of ethane-1 hydroxy-1, 1-Diphosphonate (5 mg/kg/day dose) onquantitative bone histology in paget's disease of boneMetabolic Bone Disease and Related Research, 1981
- The action of the main therapeutic regimes on paget's disease of bone, with a note on the effect of vitamin d deficiencyArthritis & Rheumatism, 1980